Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients

Vauloup‐Fellous, Christelle; Maylin, Sarah; Périllaud-Dubois, Claire; Brichler, Ségolène; Alloui, Chakib; Gordien, Emmanuel; Rameix‐Welti, Marie‐Anne; Gault, Elyanne; Moreau, F.; Fourati, Slim; Challine, Dominique; Pawlotsky, Jean‐Michel; Houhou‐Fidouh, Nadhira; Damond, Florence; Mackiewicz, Vincent; Charpentier, Charlotte; Méritet, Jean–François; Rozenberg, Flore; Podglajen, Isabelle; Marot, Stéphane; Petit, Héloïse; Burrel, Sonia; Akhavan, Sepideh; Leruez‐Ville, Marianne; Avettand-Fènoël, Véronique; Fourgeaud, Jacques; Guilleminot, Tiffany; Gardiennet, Elise; Bonacorsi, Stéphane; Carol, Agnès; Carcelain, Guislaine; Villemonteix, Juliette; Boukli, Narjis; Gozlan, Joël; Morand‐Joubert, Laurence; LeGoff, Jérôme; Delaugerre, Constance; Chaix, Marie‐Laure; Roque-Afonso, Ana-Maria; Dortet, Laurent; Naas, Thierry; Ronat, Jean-Baptiste; Lepape, Samuel; Marcelin, Anne‐Geneviève; Descamps, Diane

doi:10.1007/s10096-021-04232-3

Cited by 12 publications

(9 citation statements)

References 20 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 33 False positives are rare and may relate to cross-seropositivity with other coronaviruses or infectious agents or the presence of rheumatoid factor. 34 In our study, the possibility of centralised analysis of the samples is a strength to allow good reproducibility in the detection and quantification of anti-SARS-CoV-2 antibodies and an asset for the longitudinal follow-up, which is planned until 1 year.…”

Section: Discussionmentioning

confidence: 99%

Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

Louapre

Ibrahim

Maillart

et al. 2021

J Neurol Neurosurg Psychiatry

Self Cite

View full text Add to dashboard Cite

BackgroundSARS-CoV-2 seroconversion rate after COVID-19 may be influenced by disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMO-SD).ObjectiveTo investigate the seroprevalence and the quantity of SARS-CoV-2 antibodies in a cohort of patients with MS or NMO-SD.MethodsBlood samples were collected in patients diagnosed with COVID-19 between 19 February 2020 and 26 February 2021. SARS-CoV-2 antibody positivity rates and Ig levels (anti-S IgG titre, anti-S IgA index, anti-N IgG index) were compared between DMTs groups. Multivariate logistic and linear regression models were used to estimate the influence of DMTs and other confounding variables on SARS-CoV-2 serological outcomes.Results119 patients (115 MS, 4 NMO, mean age: 43.0 years) were analysed. Overall, seroconversion rate was 80.6% within 5.0 (SD 3.4) months after infection. 20/21 (95.2%) patients without DMT and 66/77 (85.7%) patients on DMTs other than anti-CD20 had at least one SARS-CoV-2 Ig positivity, while this rate decreased to only 10/21 (47.6%) for patients on anti-CD20 (p<0.001). Being on anti-CD20 was associated with a decreased odd of positive serology (OR, 0.07 (95% CI 0.01 to 0.69), p=0.02) independently from time to COVID-19, total IgG level, age, sex and COVID-19 severity. Time between last anti-CD20 infusion and COVID-19 was longer (mean (SD), 3.7 (2.0) months) in seropositive patients compared with seronegative patients (mean (SD), 1.9 (1.5) months, p=0.04).ConclusionsSARS-CoV-2 antibody response was decreased in patients with MS or NMO-SD treated with anti-CD20 therapies. Monitoring long-term risk of reinfection and specific vaccination strategies in this population may be warranted.Trial registration numberNCT04568707.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

Louapre

Ibrahim

Maillart

et al. 2021

J Neurol Neurosurg Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are other published evaluation reports that have similarly shown poor serological RDT performance compared to that reported by the manufacturer (Deeks et al 2020;Jacobs et al 2020;Vauloup-Fellous et al 2021). Since some of these other studies used samples from any qRT-PCR positive individuals, they show lower sensitivity in the first week post symptom onset with improved performance at later time points.…”

Section: Discussionmentioning

confidence: 91%

Evaluation of the performance of 25 SARS-CoV-2 serological rapid diagnostic tests using a reference panel of plasma specimens at the Uganda Virus Research Institute

Lutalo

Nalumansi

Olara

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Introduction Serological testing is needed to better understand the epidemiology of the SARS-CoV-2 virus. Rapid Diagnostic Tests (RDTs) have been developed to detect specific antibodies, IgM and IgG, to the virus. We evaluated the performance of 25 of these RDTs. Methods A serological reference panel of 50 positive and 100 negative plasma specimens was developed from SARS-CoV-2 PCR and antibody positive patients and pre-pandemic SARS-CoV-2-negative specimens collected in 2016. Test performance of the 25 RDTs was evaluated against this panel. Results A total of 10 RDTs had a sensitivity ≥98% while 13 RDTs had a specificity ≥98% to anti-SARS-CoV-2 IgG antibodies. Four RDTs; Boson, MultiG, Standard Q and ViviaDiag had both sensitivity and specificity of ≥98% to anti-SARS-CoV-2 IgG antibodies. Only 3 RDTs had a sensitivity ≥98% while 10 RDTs had a specificity ≥98% to anti-SARS-CoV-2 IgM antibodies. Three RDTs; Autobio, MultiG and Standard Q, had sensitivity and specificity of ≥98% to combined IgG/IgM. The RDTs that performed well also had perfect or almost perfect inter-reader agreement. Conclusions This evaluation identified three RDTs with a sensitivity and specificity to IgM/IgG antibodies of ≥98% with the potential for widespread antibody testing in Uganda.

show abstract

“…It was decided to perform different determinations previously checked in the Microbiology Department due to the disparity in the ndings re ected in some studies [17].…”

Section: Methodsmentioning

confidence: 99%

Seroprevalence of Anti-Sars-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease

Martín-Arranz

García-Ramírez

Hernández‐Pérez

et al. 2023

Preprint

View full text Add to dashboard Cite

Patients with inflammatory bowel disease (IBD) treated with biologic and/or immunosuppressant drugs are at increased risk for opportunistic infections. Seroprevalence studies can confirm the diagnosis of SARS-CoV-2 infections as well as the associated risk factors. This is a descriptive study which primary endpoints were to highlight the prevalence of SARS-CoV-2 antibodies in a cohort of IBD patients, and to analyze seroconversion in patients with known COVID-19 infection and its relationship with IBD treatments. Patients filled in a questionnaire about symptoms of COVID-19 infection and clinical information about their IBD. All included patients were tested for SARS-CoV-2 antibodies. 392 patients were included. Among patients with clinical infection, 69 patients (17,65%) were IgG-positive, 286 (73,15%) IgG-negative and 36 (9,21%) indeterminate. In relation to seroconversion among patients under biologic treatment, 13 patients of the 23 with a previous positive CRP developed antibodies (56.5%). However, when the influence of immunosuppressive treatment on the probability of developing antibodies was analyzed, no significant differences were seen between those patients with or without treatment (77.8% vs. 77.1%, p=0.96). In our cohort of IBD patients, after one year of pandemic, there were 18.64% IgG positive patients, a higher prevalence than the general population (15.7%).

show abstract

Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients

Cited by 12 publications

References 20 publications

Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

Evaluation of the performance of 25 SARS-CoV-2 serological rapid diagnostic tests using a reference panel of plasma specimens at the Uganda Virus Research Institute

Seroprevalence of Anti-Sars-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease

Contact Info

Product

Resources

About